Rein Therapeutics
RNTX
27 hedge funds and large institutions have $8.49M invested in Rein Therapeutics in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0.03% less ownership
Funds ownership: 0.38% → 0.35% (-0.03%)
18% less funds holding
Funds holding: 33 → 27 (-6)
28% less capital invested
Capital invested by funds: $11.8M → $8.49M (-$3.34M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$403K |
| 2 |
Millennium Management
New York
|
+$166K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$114K |
| 4 |
Morgan Stanley
New York
|
+$85.2K |
| 5 |
State Street
Boston,
Massachusetts
|
+$48.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.32M |
| 2 |
Squarepoint
New York
|
-$117K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$91.8K |
| 4 |
Norges Bank
Oslo,
Norway
|
-$68.3K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$68K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
26
Ameritas Investment Partners
Lincoln,
Nebraska
| $3K | – | – | – |
|
|
AG
27
Advisor Group
Phoenix,
Arizona
| $1K | – | – | – |
|
|
SFM
28
Sphera Funds Management
Tel Aviv,
Israel
| – | -$1.32M | -6,250 | Closed |
|
|
29
Squarepoint
New York
| – | -$117K | -554 | Closed |
|
|
TCIM
30
TIAA CREF Investment Management
New York
| – | -$68K | -322 | Closed |
|
|
TA
31
Teachers Advisors
New York
| – | -$62K | -295 | Closed |
|
32
UBS Group
Zurich,
Switzerland
| – | -$18K | -88 | Closed |
|
33
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8K | -40 | Closed |
|
34
Parallax Volatility Advisers
San Francisco,
California
| – | -$8K | -40 | Closed |
|
RNTX Hedge Fund Activity: Q1 2018 in Review
27 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2018, worth a combined $8.49M — down 28% from $11.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of RNTX and 1 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 12 added.
The largest buyer was Jennison Associates, adding an estimated $403K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.32M sold.
- 27 institutional investors held Rein Therapeutics (RNTX) as of Q1 2018, down from 33 in Q4 2017.
- Funds reported $8.49M of Rein Therapeutics stock for Q1 2018, down 28% quarter-over-quarter.
- 1 fund opened new Rein Therapeutics positions in Q1 2018 and 7 closed out, a net change of -6 holders.
- The largest Rein Therapeutics buyer in Q1 2018 was Jennison Associates, an estimated $403K added.
- The largest Rein Therapeutics seller in Q1 2018 was Sphera Funds Management, an estimated $1.32M sold.
Based on aggregated 13F filings for Q1 2018.